Back

Single-Cell Atlas of Renal Cell Carcinoma Brain Metastasis Uncovers Mechanisms of Immune Dysfunction and Resistance

Ali, M. I. H.; Feyza Akpinar, Z.; A Ovando-Ricardez, J.; Casasent, A. K.; Lam, T. N. A.; Lin, J.; Khanmammadova, N.; Reville, P. K.; Shih, D. J. H.; Osunkoya, A. O.; Norberg, L. M.; Tran, T. M.; Li, J.; Hoang, A. G.; Hanalioglu, S.; Bilen, M. A.; Lang, F.; Huse, J. T.; Navin, N.; Hasanov, M.; Jonasch, E.; Hasanov, E.

2026-05-10 cancer biology
10.64898/2026.05.06.722652 bioRxiv
Show abstract

Brain metastasis (BM) in renal cell carcinoma (RCC) remains poorly understood and often resistant to immune checkpoint inhibitors. We generated a large single-nucleus RNA-seq data of RCC BM, profiling 14 BM samples alongside matched extracranial metastases and primary tumors. Tumor cells in BM displayed neuronal infiltration, neural-like adaptation, and marked remodeling of the microenvironment, including expansion of immunosuppressive myeloid cells and depletion of antigen-presenting dendritic cells. Tumor, immune, and stromal cells exhibited metabolic rewiring characterized by fatty-acid metabolism, oxidative phosphorylation, and MYC-driven programs. CD8 T cells showed terminal exhaustion and impaired proliferative capacity, and tertiary lymphoid structures were absent. Spatial profiling of 12 BM samples (13,128 cells) validated key cellular interactions, while ligand-receptor analysis revealed immunoregulatory circuits between tumor, stromal, and immune cells. These findings define BM-specific adaptations that promote immune evasion and resistance, revealing therapeutic vulnerabilities in RCC BM. SIGNIFICANCESingle-nucleus RNA-sequencing profiling reveals tumor, immune, and metabolic adaptations in renal cell carcinoma (RCC) brain metastases, including neuroglial remodelling and immunosuppressive niche formation. These findings identify immune evasion mechanisms that could contribute to therapeutic resistance, providing new avenues for site-specific therapeutic interventions to improve treatment efficacy and outcomes in patients with RCC BM.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 13%
13.8%
2
Cancer Discovery
61 papers in training set
Top 0.1%
12.0%
3
Nature Cancer
35 papers in training set
Top 0.1%
8.1%
4
Nature
575 papers in training set
Top 5%
6.1%
5
Genome Medicine
154 papers in training set
Top 2%
3.8%
6
Cell Reports
1338 papers in training set
Top 14%
3.8%
7
Journal of Clinical Investigation
164 papers in training set
Top 1%
3.4%
50% of probability mass above
8
Cancer Research
116 papers in training set
Top 1%
3.4%
9
Cell Reports Medicine
140 papers in training set
Top 2%
3.4%
10
Nature Cell Biology
99 papers in training set
Top 2%
2.6%
11
Nature Genetics
240 papers in training set
Top 3%
2.5%
12
Cancer Cell
38 papers in training set
Top 0.7%
2.4%
13
Science
429 papers in training set
Top 12%
2.4%
14
Cell Stem Cell
57 papers in training set
Top 0.9%
2.0%
15
Cell
370 papers in training set
Top 12%
1.6%
16
Cell Genomics
162 papers in training set
Top 4%
1.6%
17
Developmental Cell
168 papers in training set
Top 9%
1.6%
18
Gastroenterology
40 papers in training set
Top 1%
1.3%
19
Journal of Experimental Medicine
106 papers in training set
Top 3%
1.3%
20
eLife
5422 papers in training set
Top 48%
1.3%
21
Cell Metabolism
49 papers in training set
Top 2%
1.2%
22
Molecular Cell
308 papers in training set
Top 9%
1.2%
23
Immunity
58 papers in training set
Top 3%
1.2%
24
Nature Metabolism
56 papers in training set
Top 2%
1.1%
25
Science Advances
1098 papers in training set
Top 26%
0.9%
26
Nature Medicine
117 papers in training set
Top 4%
0.9%
27
Oncogene
76 papers in training set
Top 2%
0.7%
28
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 46%
0.7%
29
Neuro-Oncology
30 papers in training set
Top 0.8%
0.7%
30
Science Translational Medicine
111 papers in training set
Top 7%
0.7%